Baxter Boosts Oncology Pipeline With $900M Cross-Border Deal

NEW YORK (The Deal) -- Baxter International (BAX) is preparing to break itself up in the coming months but that hasn't stopped it from inking a $900 million deal to build up its pipeline of products in the white hot sector of oncology.

Deerfield, Ill.-based Baxter said Tuesday it would spend $900 million in stock to acquire the Oncaspar Leukemia portfolio of Italy's Sigma Tau Finanziaria SpA for $900 million. The deal includes Oncaspar, a treatment for Acute Lymphoblastic Leukemia (ALL), a cancer of the white blood cells, as well as pipeline candidate Calaspargase Pegol -- a new biologic in treatment of ALL.

If you liked this article you might like

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

These Stocks Are Ready to Reverse Course

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways